Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is an innovative healthcare technology company using AI in diagnostics to support oncology and rare diseases. They have a decentralized model and strategic partnerships, which are key drivers for future growth. With a projected market value of $40B and a focus on the US market, the company has a strong global presence and a robust data network that generates recurring revenue. Additionally, Sophia Genetics has a strong cash position and is expected to achieve profitability in the medium term, making it a promising investment opportunity for those with a positive outlook on the company's future.

Bears say

Sophia Genetics is facing fierce competition in the growing field of AI-based precision medicine, with centralized testing providers, platform players, and sequencer manufacturers all vying for market share. Additionally, the company's heavy focus on data has resulted in significant cybersecurity risks and a potential reliance on patents licensed from third parties. In spite of strong growth metrics, the company remains unprofitable and faces uncertainty in achieving profitability in the near future. The company's high valuation multiples and reliance on future revenue growth make it a risky investment.

SOPH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 3 analysts, SOPH has a Strong Buy consensus rating as of Aug 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.